New hope for lung cancer patients with brain-spread disease
NCT ID NCT07551414
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a combination of the drug zorifertinib plus chemotherapy delivered directly into the fluid around the brain and spine. It is for people with a specific type of lung cancer (NSCLC with EGFR mutation) whose cancer has spread to the lining of the brain and spinal cord after previous treatment. The study will enroll 38 adults to see if the combination can shrink or stop the spread.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zorifertinib plus intra-Ommaya chemotherapy
- What this could lead to
- If it works, this could offer a new treatment option for lung cancer that has spread to the lining of the brain and spinal cord.
- What could go wrong
- This is a small, early-phase trial with only 38 participants, so results may not apply to everyone. The combination therapy may cause side effects or fail to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EGFR-TKI SENSITIZING MUTATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
National Cancer Center/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
- Spinal fluid injection of Dual-Target antibody and chemotherapy shows promise for deadly cancer complication
- Smartwatch could alert doctors to brain cancer complications before they worsen
- Blood test may let cancer patients take safe breaks from immunotherapy
- Triple therapy targets tough brain metastases in lung cancer
- Experimental combo for tough cancers shows early promise, but trial halted